PT  - JOURNAL ARTICLE
AU  - Robles, Edgar E.
AU  - Jin, Ye
AU  - Smyth, Padhraic
AU  - Scheuermann, Richard H.
AU  - Bui, Jack D.
AU  - Wang, Huan-You
AU  - Oak, Jean
AU  - Qian, Yu
TI  - A cell-level discriminative neural network model for diagnosis of blood cancers
AID  - 10.1101/2023.02.07.23285606
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.07.23285606
4099  - http://medrxiv.org/content/early/2023/02/10/2023.02.07.23285606.short
4100  - http://medrxiv.org/content/early/2023/02/10/2023.02.07.23285606.full
AB  - Motivation Precise identification of cancer cells in patient samples is essential for accurate diagnosis and clinical monitoring but has been a significant challenge in machine learning approaches for cancer precision medicine. In most scenarios, training data are only available with disease annotation at the subject or sample level. Traditional approaches separate the classification process into multiple steps that are optimized independently. Recent methods either focus on predicting sample-level diagnosis without identifying individual pathologic cells or are less effective for identifying heterogeneous cancer cell phenotypes.Results We developed a generalized end-to-end differentiable model, the Cell Scoring Neural Network (CSNN), which takes the available sample-level training data and predicts both the diagnosis of the testing samples and the identity of the diagnostic cells in the sample, simultaneously. The cell-level density differences between samples are linked to the sample diagnosis, which allows the probabilities of individual cells being diagnostic to be calculated using backpropagation. We applied CSNN to two independent clinical flow cytometry datasets for leukemia diagnosis. In both qualitative and quantitative assessments, CSNN outperformed preexisting neural network modeling approaches for both cancer diagnosis and cell-level classification. Post hoc decision trees and 2D dot plots were generated for interpretation of the identified cancer cells, showing that the identified cell phenotypes match the cancer endotypes observed clinically in patient cohorts. Independent data clustering analysis confirmed the identified cancer cell populations.Availability The source code of CSNN and datasets used in the experiments are publicly available on GitHub and FlowRepository.Contact Edgar E. Robles: roblesee{at}uci.edu and Yu Qian: mqian{at}jcvi.orgSupplementary information Supplementary data are available on GitHub and at Bioinformatics online.Competing Interest StatementDr. Yu "Max" Qian has consulted for Moderna, Inc.Funding StatementThis work has been partially supported by the FlowGate project (NCATS U01TR001801) funded by the National Center for Advancing Translational Sciences at the U.S. National Institutes of Health and an Investigator Sponsored Study Award (Protocol 68754391) from Becton, Dickinson and Company (BD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Datasets used in the study were collected using standard diagnostic protocols at University of California, San Diego and Stanford University. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. All datasets were de-identified before data transfer and analytics. Internal Review Board (IRB) of University of California, San Diego and Internal Review Board (IRB) of Stanford University have provided approval for the research work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe source code of the CSNN can be downloaded at GitHub: https://github.com/erobl/csnn. The de-identified B-ALL dataset is publicly accessible on FlowRepository under accession FR-FCM-Z6YK. The CLL dataset was converted to TXT format during de-identification, which can be downloaded at GitHub: https://github.com/JCVenterInstitute/DAFi-gating/tree/master/CSNN/CLL_TXT. 2D dot plots for comparing CSNN with other methods can also be found at GitHub: https://github.com/JCVenterInstitute/DAFi-gating/tree/master/CSNN/Comparison_with_CellCNN_DeepCellCNN. https://flowrepository.org/id/FR-FCM-Z6YK https://github.com/JCVenterInstitute/DAFi-gating/tree/master/CSNN